

POLICY FOR TREATMENT OF LOWER RESPIRATORY TRACT INFECTIONS

Written by: Dr Nick Lewis, Consultant in Infection

Date: August 2024; Amended Sept 2025

Approved by: The Drugs & Therapeutics Committee

Implementation
Date: September 2025

For Review: August 2027

*This document is part of antibiotic formulary guidance
Formulary guidance holds the same status as Trust policy*

Lower Respiratory Tract Infections

1) [Community Acquired Pneumonia \(CAP\)](#)

- a. Definition
- b. Investigations
- c. Treatment

2) [Hospital Acquired Pneumonia \(HAP\)](#)

- a. Definition
- b. Investigations
- c. Treatment

3) [Aspiration pneumonia](#)

- a. Definition
- b. Investigations
- c. Treatment

4) [COPD/Non-CF Bronchiectasis](#)

- a. Definition
- b. Investigations
- c. Treatment

5) [Lung abscess/Empyema thoracis](#)

- a. Definition
- b. Investigations
- c. Treatment

AMENDMENTS

Date	Summary of Changes	Author
Sept 2025	Minor amendment to include IV or PO macrolide to antibiotic treatment option for CAP CURB score 3. Inclusion of recommended investigations for moderate and high severity CAP.	Dr B Subramanian

1) Community acquired pneumonia (CAP)

Definition

Acute respiratory tract illness associated with a CXR showing a new infiltrate, occurring prior to or within first two days of admission to hospital (i.e. acquired outside hospital), **including pneumonia that develops in a nursing home resident.**

CAP should be confirmed by CXR before commencement of antibiotics in the majority of patients. Selected patients with life-threatening disease should be treated based on a presumptive clinical diagnosis of CAP. Sometimes an initial CXR can be normal, so consider repeating after 24 hours if high index of suspicion. If repeat CXR is normal, consider other diagnoses.

Common causative organisms	Microbiological Investigations
<i>Streptococcus pneumoniae</i> <i>Haemophilus influenzae</i> Respiratory viruses particularly in children Mycoplasma <i>Chlamydophila pneumoniae</i> <i>Legionella pneumophila</i> <i>Staphylococcus aureus</i> especially following influenza virus infection	Sputum cultures Blood culture (moderate/severe) Legionella urine antigen (in suspected atypical pneumonia) or if CURB ≥ 3 Mycoplasma serology (in suspected atypical pneumonia) Nasopharyngeal swabs for viral PCR (if indicated) HIV screen (particularly in confirmed pneumococcal pneumonia)

Assess CURB-65 score (one point for each):

- **C**onfusion (new onset)
- **U**rea >7 mmol/l
- **R**esp rate >30 /min
- **B**lood pressure(SBP <90 mmHg or DBP <60 mmHg)
- Age >65 years.

Treatment

CURB65 score	1 st line	Penicillin allergy	If <u>MRSA</u> colonised in nose, throat or sputum:	Duration	Comments
0-1 <i>(Low severity)</i>	Amoxicillin 500mg TDS PO	1st line: Doxycycline 200mg stat, then 100mg OD PO OR 2nd line: Clarithromycin 500mg BD PO (Erythromycin 500mg QDS po if pregnant)		5 days	For CURB score ≥ 2, send appropriate investigations: -Sputum MC&S -Blood cultures -Mycoplasma serology -Urine pneumococcal & legionella antigen -Throat swab for viral PCR if appropriate (e.g. during flu season) -HIV screen for confirmed pneumococcal pneumonia
2 <i>(Moderate severity)</i>	Amoxicillin 500mg-1g TDS PO AND Clarithromycin 500mg BD PO (Erythromycin 500mg QDS po if pregnant) OR (if unable to take orally) Benzylpenicillin 1.2g QDS IV AND Clarithromycin 500mg BD IV (Erythromycin 500mg QDS IV if pregnant)	Doxycycline 200mg stat, then 100mg OD PO (If allergic/intolerant to doxycycline, contact Infection Consultant)	Addition of MRSA-active antibiotic may be indicated – please discuss with Infection Consultant	Some organisms may require longer duration: Legionella: 14 days Mycoplasma: 7-14 days Staph aureus (incl MRSA): 14-21 days	
3-5 <i>(High severity)</i>	Co-amoxiclav 1.2g TDS IV AND Clarithromycin 500mg BD IV/ PO (Erythromycin 500mg QDS IV/PO if pregnant)	Penicillin allergy (non life- threatening) Cefuroxime 1.5g TDS IV AND Clarithromycin 500mg BD IV/PO (Erythromycin 500mg QDS IV/PO if pregnant) Penicillin allergy (anaphylaxis): Co-trimoxazole 960mg BD PO/IV + Clarithromycin 500mg BD PO/IV		If no improvement after 48-72 hours seek advice from Infection consultant	Consider Critical Care review Review with microbiology results and switch to narrow spectrum agent where possible

Notes:

- Antibiotics should be administered within 4 hours of presentation.
- For High Risk Sepsis refer to the Trust sepsis IPOC
- Antibiotics may need renal dose adjustment – refer to Renal Handbook or discuss with Pharmacist

- **Switch to:**
 - A specific narrow spectrum therapy based on Microbiology results should be considered e.g. benzylpenicillin alone for Pneumococcus.
 - Oral therapy after clinical improvement has occurred (usually after 24-48hr of IV therapy), unless sensitivity results indicate that the switch cannot be made.

- **Panton-Valentine Leucocidin (PVL) positive *Staphylococcus aureus* :**
 - Causes necrotising pneumonia, frequently following influenza infection and can occur in young fit patients. Please discuss with Infection Consultant for advice on management if this is suspected.

2) Hospital acquired pneumonia (HAP)

Definition

Pneumonia (see definition above) that occurs ≥ 2 days after admission and did not seem to have been incubating on admission, with new or progressive consolidation on CXR.

This **does not include** patients with a recent admission to hospital, unless they were **discharged within the previous 48 hours. All other patients should be treated as per CAP guidelines above.**

Ventilator associated pneumonia (VAP) is a type of pneumonia that occurs more than 48hrs after endotracheal intubation.

Common causative organisms	Microbiological Investigations
<i>Pseudomonas aeruginosa</i> <i>Staphylococcus aureus</i> <i>Haemophilus influenzae</i> <i>Streptococcus pneumoniae</i> <i>Streptococcus sp</i> Enterobacterales (eg <i>E.coli</i> , <i>Klebsiella</i> , <i>Enterobacter</i>)	Blood culture Sputum BAL (if indicated) Viral PCR (if indicated)

Treatment notes:

- Switch to oral treatment as soon as clinical improvement occurs.
- For patients with **previous history of confirmed toxigenic *C.difficile* infection** please discuss with Infection consultant.
 - † **Fluoroquinolone warning:**
 - Fluoroquinolones should not be used for mild-moderate infections, unless other antibiotics cannot be used.
 - The European Medicines Agency's Pharmacovigilance Risk Assessment Committee has recommended restricting the use of fluoroquinolone antibiotics following a review of side effects mainly involving muscles, tendons, bones, nervous system and in those at high risk of aortic aneurysm.
 - **Patients should be warned about these side effects, which are rare but can be disabling and potentially long-lasting.** A [Patient Information Leaflet](#) is available [here](#).

[Click here for further information.](#)

Treatment

Hospital acquired pneumonia		If <u>MRSA</u> colonised in nose, throat or sputum:	Duration	Comments
1 st line	<p>Co-amoxiclav 1.2g TDS IV (if not taking orally) OR Co-amoxiclav PO 625mg TDS</p> <p>Penicillin allergy (non life-threatening) Cefuroxime 1.5g TDS IV OR Cefaclor MR 375mg PO BD</p>	Addition of MRSA-active antibiotic may be indicated – please discuss with Infection Consultant	5 days If no improvement after 48-72 hours seek advice from Infection team	
<p>2nd line</p> <p>If no response after 48hrs to above OR Age >65 AND ≥ 5 days treatment with co-amoxiclav or cephalosporin (for any indication) that has finished within the last 2 weeks.</p>	<p>* Piperacillin-tazobactam 4.5g TDS IV</p> <p>Oral switch: Levofloxacin 500mg BD PO †</p> <p>Penicillin allergy (life threatening) Vancomycin (follow Trust guideline for dosing) + Aztreonam 2g TDS IV</p> <p>Oral Switch: Levofloxacin 500mg BD PO †</p>			<p>*If patient has had treatment with > 5 days of co-amoxiclav followed by piperacillin-tazobactam with symptoms unresolved, contact Consultant in Infection</p> <p>† See fluoroquinolone warning above.</p>

3) Aspiration Pneumonia

Definition

Pneumonia, usually of insidious onset, resulting from 'macroaspiration' of oropharyngeal or gastric contents colonised with bacteria. Usually the aspiration is not witnessed; therefore aspiration pneumonia commonly applies to pneumonia in a patient with risk factors for aspiration. These risk factors include altered consciousness, abnormal gag and swallowing reflexes, stroke and gastric disorders such as gastro-oesophageal reflux. It should be distinguished from aspiration pneumonitis, an acute chemical lung injury after the inhalation of regurgitated sterile gastric contents in which aspiration is commonly witnessed.

Please note: in uncomplicated chemical pneumonitis, there is no role for prophylactic antibiotics within 48h of aspiration. There is also a risk of developing antimicrobial resistance.

Common causative organisms	Microbiological Investigations
Anaerobes <i>Staphylococcus aureus</i> Gram negative bacilli (including <i>Pseudomonas</i>) <i>Streptococcus pneumoniae</i> <i>Haemophilus influenzae</i>	Blood cultures Sputum cultures

Treatment

Aspiration pneumonia		Oral switch	If <u>MRSA</u> colonised in nose, throat or sputum:	Duration	Comments
1st line	<p>No treatment. Many patients with a chemical aspiration pneumonitis do <u>NOT</u> require antibiotic treatment (unless the patient is severely ill). Antibiotics are only recommended if:</p> <ul style="list-style-type: none"> • There is no resolution after 48hrs, associated with pulmonary infiltrates on CXR. • The features are those of a bacterial pneumonia of the more insidious form. 				
2nd line	Unless meet criteria for piperacillin + tazobactam below	Co-amoxiclav 1.2g TDS IV	Co-amoxiclav 625mg TDS	Addition of MRSA-active antibiotic may be indicated – please discuss with Infection Consultant	5 days
Penicillin allergy (non life-threatening)		Cefuroxime 1.5g TDS IV	Cefaclor MR 375mg BD		
Life threatening penicillin allergy (anaphylaxis)		Vancomycin IV (follow Trust guideline) + Aztreonam 2g TDS IV	Co-trimoxazole 960mg BD PO		
<p><u>Criteria for Piperacillin + tazobactam:</u></p> <p>Age >65 years</p> <p>AND ≥ 5 days treatment with co-amoxiclav or cephalosporin (for any indication) that has finished within the last 2 weeks.</p>		<p>*Piperacillin + tazobactam 4.5g TDS IV</p> <p>Penicillin allergy: Co-trimoxazole 960mg BD IV/PO</p>	Discuss with Infection consultant		<p>* If patient has had treatment with > 5 days of co-amoxiclav followed by piperacillin + tazobactam with symptoms unresolved, contact Infection Consultant</p>

4) COPD/Non-CF Bronchiectasis

Definition

COPD is a chronic, slowly progressive disorder characterised by airflow limitation that is not fully reversible, associated with an abnormal inflammatory response of the lungs to noxious particles or gases.

Bronchiectasis is a chronic disease causing chronic daily cough with viscid sputum production following irreversible dilatation of the bronchi due to bronchial wall damage caused by infection or inflammation.

Exacerbations of COPD/bronchiectasis are defined as a sustained change in the patient's dyspnoea, cough and/or sputum production (colour or volume) beyond day- to-day variability sufficient to warrant a change in management. They may be due to infective or non-infective (e.g. air pollution) causes.

Common causative organisms	Microbiological Investigations
<i>Haemophilus influenzae</i> <i>Moraxella catarrhalis</i> <i>Streptococcus pneumoniae</i> <i>Pseudomonas aeruginosa</i>	Sputum Blood culture (if systemically unwell)

Notes:

† Fluoroquinolone warning:

- Fluoroquinolones should not be used for mild-moderate infections, unless other antibiotics cannot be used.
- The European Medicines Agency's Pharmacovigilance Risk Assessment Committee has recommended restricting the use of fluoroquinolone antibiotics following a review of side effects mainly involving muscles, tendons, bones, nervous system and in those at high risk of aortic aneurysm.
- **Patients should be warned about these side effects, which are rare but can be disabling and potentially long-lasting.** A Patient Information Leaflet is available [here](#).

[Click here for further information.](#)

Treatment

Infective exacerbation of COPD/Bronchiectasis		If <u>MRSA</u> colonised in nose, throat or sputum:	Duration	Comments
1 st line	<p>Doxycycline 200mg stat, then 100mg OD PO</p> <p>OR</p> <p>Amoxicillin 500mg-1000mg TDS PO/IV</p> <p>OR</p> <p>Clarithromycin 500mg BD PO/IV</p>			Only use IV if unable to take orally or patient severely ill.
<p>If <u>no previous <i>Pseudomonas</i></u> in sputum AND documented resistance to 1st line agents</p> <p>OR</p> <p>no response to 1st line agent after 48hrs.</p>	<p>Co-amoxiclav 1.2g TDS IV OR 625mg TDS PO</p> <p><u>Penicillin allergy (non-life threatening)</u></p> <p>Cefuroxime 1.5g TDS IV</p> <p>OR Cefaclor MR 375mg BD PO</p> <p><u>Penicillin allergy (life threatening)</u></p> <p>Co-trimoxazole 960mg BD IV/PO</p>	<p>Addition of MRSA-active antibiotic may be indicated – please discuss with Infection Consultant</p>	<p><u>COPD</u></p> <p>5 days</p> <p><u>Bronchiectasis</u></p> <p>7-14 days</p>	<p>Adjust antibiotic treatment based on culture results</p>
<p><u><i>Pseudomonas</i></u> previously isolated from sputum AND severely unwell.</p> <p>OR</p> <p><u><i>Pseudomonas</i></u> previously isolated from sputum AND no response to 1st line after 48hrs.</p>	<p>Piperacillin-tazobactam 4.5g QDS IV</p> <p><u>Penicillin allergy (non-life threatening)</u></p> <p>Ceftazidime 2g TDS IV</p> <p><u>Penicillin allergy (life threatening)</u></p> <p>Ciprofloxacin 750mg BD PO [†]</p>			<p>[†] See fluoroquinolone warning above.</p>

5) Lung abscess/Empyema thoracis

Definitions

Lung abscess is a localised collection of pus within a cavitating lesion in the lung parenchyma with a CXR that shows a cavity with an air- fluid level. The clinical features include cough with large amounts of foul-smelling sputum often with fever, haemoptysis, weight loss and malaise. Aspiration is the main predisposing factor with bronchial obstruction, bronchiectasis, infarction due to PE with secondary bacterial infection, necrotising pneumonia, tuberculosis and septic embolisation (infective endocarditis or suppurative phlebitis) accounting for the rest.

Empyema thoracis is defined as the presence of pus in the pleural cavity. It may be secondary to pneumonia or may be due to ruptured oesophagus, subphrenic/hepatic abscess, post-thoracic surgery or penetrating injury of the chest.

Common causative organisms	Microbiological Investigations
Anaerobes <i>Streptococcus milleri</i> <i>Staphylococcus aureus</i> Aerobic gram negative bacilli especially <i>Klebsiella spp</i> <i>Mycobacterium tuberculosis</i> <i>Streptococcus pneumoniae</i> (esp Empyema) In immunocompromised host: <i>-Pseudomonas aeruginosa, Nocardia & fungi</i>	Sputum(please specify if TB is suspected) Blood cultures Pus from pleural cavity or lung abscess

Treatment

Lung abscess/Empyema thoracis		If <u>MRSA</u> colonised in nose, throat or sputum:	Duration	Comments
1 st line	Co-amoxiclav 1.2g TDS IV	Addition of MRSA-active antibiotic may be indicated – please discuss with Infection Consultant	Please discuss with Infection Consultant as the antibiotic treatment will be prolonged (e.g. until CXR shows small stable lesion or is clear). Treatment may require adjusting after culture results.	Drainage of empyema is critical for source control
2 nd line Penicillin allergy (non-life threatening)	Cefuroxime 1.5g TDS IV AND Metronidazole 500mg TDS IV			
3 rd line Penicillin allergy (life threatening)	Co-trimoxazole 960mg BD IV/PO AND Metronidazole 500mg TDS IV (or 400mg TDS PO)			

Notes: Please discuss with Consultant in Infection in following cases:

- For patients with **previous history of confirmed toxigenic *C.difficile* infection**
- **If immunocompromised patient or any risk/suspicion of TB**